FDA Removes Partial Clinical Hold from Idenix Pharma's (IDIX) IDX184
Up)
Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX) today announced that it has received notification from the U.S. FDA that the partial clinical hold on IDX184 has been removed and that the Company's 12-week phase IIb study evaluating IDX184 in combination with pegylated interferon and ribavirin (PegIFN/RBV) may continue.
IDX184 has demonstrated a high barrier to resistance in vitro and potent antiviral activity in both preclinical and clinical studies. Recently announced interim phase IIb data demonstrated favorable antiviral activity and no serious adverse events.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
IDX184 has demonstrated a high barrier to resistance in vitro and potent antiviral activity in both preclinical and clinical studies. Recently announced interim phase IIb data demonstrated favorable antiviral activity and no serious adverse events.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
You May Also Be Interested In
- Auxilium (AUXL) Files Suit Against Watson (WPI) Over Testim 1% Gel
- Catalyst Pharmaceutical (CPRX) Reports Encouraging Data from CPP-115 Phase Ia
- Cytokinetics (CYTK) Opens Second Cohort for ATOMIC-AHF Phase IIb
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
